Lilly's Prevail inks $1.5B CRISPR deal

Today's Big News

May 16, 2023

Chasing Madrigal, Viking sails higher after NASH therapy slays midphase test


'Riding a tiger' from the lab to C-suite with Mammoth's Janice Chen


Scribe's CRISPR tech Prevails in new $1.5B biobucks deal with Lilly unit


DiaMedica prepares to end 10-month FDA hold on late-phase stroke trial by halving dose


Is space the place for stem cell manufacturing? Scientists will soon test that on the ISS


Flagship launches Metaphore with $50M to mimic the molecular version of the owl butterfly


Boundless ups fundraising by Leaps and bounds, adding another $100M haul


NIH foundation, partnering with research institutions, adds 8 rare diseases to clinical trial portfolio

 

Featured

Chasing Madrigal, Viking sails higher after NASH therapy slays midphase test

Viking Therapeutics’ non-alcoholic steatohepatitis has sailed past another clinical test, this time a phase 2b that linked VK2809 to mean relative changes in liver fat of up to 51.7% without causing widespread gastrointestinal side effects.
 

Top Stories

'Riding a tiger' from the lab to C-suite with Mammoth's Janice Chen

The COVID pandemic was a make or break moment for many a biotech. For Mammoth Biosciences, it may have been both. For Janice Chen, chief technology officer and co-founder, the whole journey has been wild.

Scribe's CRISPR tech Prevails in new $1.5B biobucks deal with Lilly unit

Eli Lilly’s Prevail Therapeutics is jotting down up to $1.5 billion for Scribe Therapeutics in hopes of writing some new CRISPR-based genetic medicines for neurological and neuromuscular diseases into history.

Understanding Venture Debt Funding for Life Sciences Companies

Venture debt is a type of debt financing obtained by early and growth-stage companies and typically used as a complementary method to equity financing.

DiaMedica prepares to end 10-month FDA hold on late-phase stroke trial by halving dose

DiaMedica Therapeutics thinks it has the data to get out from under a stubborn FDA clinical hold. Ten months after its phase 2/3 stroke clinical trial suffered the setback, the biotech is on the cusp of submitting evidence designed to explain the unexpected low blood pressure events and allay concerns.

Navigating uncertainty in modern clinical development

Developing a new life-saving drug or medical device is fraught with challenges. But while challenges often vary from program to program, one in particular is guaranteed: uncertainty. In this article, Dr Kim, CMO at Cytel, discusses the nature and consequences of the uncertainty challenge, as well as the options available to help pharmaceutical and biotechnology companies navigate it.

Is space the place for stem cell manufacturing? Scientists will soon test that on the ISS

The world’s second-ever private astronaut mission to the International Space Station will ferry a first-of-its-kind experiment that will test whether scientists can create induced pluripotent stem cells in microgravity.

Flagship launches Metaphore with $50M to mimic the molecular version of the owl butterfly

Flagship is taking the sheet off its latest biotech venture, unveiling Metaphore Biotechnologies and equipping it with $50 million to get off the ground. The biotech is looking to capitalize on natural molecular mimicry to design a class of new medicines.

Boundless ups fundraising by Leaps and bounds, adding another $100M haul

Boundless Bio, the precision oncology company working on treatments for oncogene-amplified cancers, is amping up its fundraising with a new $100 million series C round backed by Leaps by Bayer and RA Capital Management.

NIH foundation, partnering with research institutions, adds 8 rare diseases to clinical trial portfolio

The Foundation for the National Institutes has tacked on eight new rare diseases to its Bespoke Gene Therapy Consortium, partnering with research institutions to advance novel therapies. The foundation's near-term goal is funding development of the trials through phase 1/2 studies.

FTC seeks to block Amgen's $28B Horizon buy in 'broadly negative' move for biopharma M&A: report

Just as biopharma's M&A prospects seemed to be improving, the U.S. antitrust watchdog is reportedly preparing to put a damper on dealmaking. The Federal Trade Commission is aiming to block Amgen’s proposed $27.8 billion acquisition of Horizon Therapeutics, Bloomberg reports.

CVS closing down clinical trials business after 2 years

CVS Health is closing down its clinical trials arm just two years after its launch, a company spokesperson confirmed to Fierce Healthcare.

Embecta dives deeper into Type 2 diabetes tech with Tidepool team-up

Embecta has teamed up with Tidepool to add an automated insulin delivery algorithm to its insulin patch pump to create a closed-loop diabetes management system for Type 2 users.

Experts call for addressing rising Black maternal mortality from all sides

During Fortune’s recent Brainstorm Health event, experts and advocates working to address the dangerous inequality Black mothers face spoke about what institutions can do to address the growing threat. The event came soon after national Black Maternal Health Week and began with a statement from the president proclaiming that “healthcare should be a right and not a privilege.”
 
Fierce podcasts

Don't miss an episode

'Podnosis': The rise of digital therapeutics, and ways to fix the PBM industry

This week on "Podnosis," we discuss the rise of digital therapeutics and remaining barriers to implementation. We also talk about what it takes to fix the PBM industry.
 

Resources

Whitepaper

ChatGPT in Drug Discovery: Rise of Large Language Models

ChatGPT shows promise in drug discovery for information extraction, scientific text authoring, hypothesis prediction, and chemical entity prediction. This whitepaper explores its potential to streamline research, delving into its technology, applications, and limitations.
Whitepaper

Discovering High-Affinity, Functional Anti-GLP-1R Antibodies

Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties.
eBook

Decentralized Clinical Trials: The Complete Guide for 2023

Discover a game-changing approach to clinical research with Hybrid and Decentralized Clinical Trials (DCTs). Learn about the benefits, challenges, and key elements for success.
Research

How Lilly’s Legal and Library Services Empower Teams Across the Drug Development Pipeline

What role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how.

Whitepaper

Medical Affairs Metamorphosis VI: The Changing Face of Stakeholder Engagement

This paper focuses on stakeholder engagement and how Medical Affairs teams’ responsibilities, goals, tools, and techniques are changing.
Research

Maximizing Clinical Trial Success

Strategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies
Whitepaper

eConsent: Flexible Consent Through Enabling Technologies

How can eConsent provide a more flexible approach to informed consent?

Whitepaper

Running Decentralized Trials at Scale

Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment.
Whitepaper

Key Clinical Supply Issues Sponsors Should Consider with their CRO

As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs.

Whitepaper

Specialized Expertise for Management of Clinical Supply Budgets

For sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management.
Whitepaper

Clinical Supply Solutions for the Asia-Pacific Region

Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region.
Whitepaper

Designing an Optimal APAC Clinical Supply Chain

Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific.
Whitepaper

Roles and Responsibilities of Specialized Clinical Supply Experts

How can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis.
Whitepaper

Supply Services to Support Clinical Trials in Japan & Beyond

Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world.
Whitepaper

Questions You Need to Ask Your CRO About Clinical Supply

Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial.
 

Industry Events

 

Upcoming Fierce Events

12-14
Jun
San Diego, CA
13
Jun
Free Virtual Event
20-22
Jun
Free Virtual Event
22
Jun
Free Virtual Event
18-19
Jul
July 18-19, 2023 | Jersey City, NJ

View all events